Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Boehringer Ingelheim | INDUSTRY |
| Research Manitoba | OTHER |
| Manitoba Health, Seniors and Long-Term Care, Province of Manitoba | UNKNOWN |
| First Nations Health and Social Secretariat of Manitoba |
Not provided
Not provided
Not provided
The goal of this clinical trial is to determine the most effective way to complete population-based screening for chronic kidney disease (CKD) in First Nations adults in Manitoba. The main questions it aims to answer are:
Participants will be randomized to:
The primary outcome is the difference between groups in the proportion of individuals who undergo screening for chronic kidney disease within 6 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient contact via mail with a letter and laboratory requisition | Other | Patient contact via mail with a letter and laboratory requisition for serum creatinine and urine albumin to creatinine ratio |
|
| Patient and primary care network contact via mail with a letter but no laboratory requisition | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| population-based screening for chronic kidney disease | Other | Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments |
|
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of individuals who undergo screening for Chronic Kidney Disease (CKD) | The proportion of individuals screened for Chronic Kidney Disease using one screening strategy is compared to the proportion of individuals screened using the other screening strategy. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| New diagnosis of CKD (Chronic Kidney Disease) | The proportion of individuals with a new diagnosis of CKD by estimated glomerular filtration rate (eGFR) or albuminuria for each screening strategy | 5 years |
| Anti-hyperintensive therapy |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Collister, MD, PhD, FRCPC | University of Manitoba | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chronic Disease Innovation Centre | Winnipeg | Canada |
Not provided
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| UNKNOWN |
| Shared Health Manitoba | UNKNOWN |
| Seven Oaks General Hospital | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The proportion of individuals treated with anti-hyperintensive therapy for each screening strategy
| 5 years |
| Renin angiotensin aldosterone inhibitor blockade treatment | The proportion of individuals treated with renin angiotensin aldosterone inhibitor blockade for each screening strategy | 5 years |
| Sodium Glucose Cotransporter 2 (SGLT2) inhibition treatment | The proportion of individuals treated with Sodium Glucose Cotransporter 2 (SGLT2) inhibition for each screening strategy | 5 years |
| Mineral corticoid receptor antagonist treatment | The proportion of individuals treated with a mineral corticoid receptor antagonist for each screening strategy | 5 years |
| Statins treatment | The proportion of individuals treated with statins for each screening strategy | 5 years |
| Anti-platelet agents treatment | The proportion of individuals treated with anti-platelet agents for each screening strategy | 5 years |
| Hospitalizations for diseases | The proportion of individuals treated with hospitalizations for acute coronary syndrome, peripheral vascular disease, cerebrovascular disease or heart failure rate. Urine albumin to creatinine ratio, kidney failure risk equation (KFRE) measurements are also calculated for each screening strategy | 5 years |
| The number of antihypertensive medications | The number of antihypertensive medications per individual for each screening strategy | 5 years |
| Change in estimated Glomerular Filtration Rate, urine albumin to creatinine ratio, kidney failure risk equation measurements | Change in estimated Glomerular Filtration Rate, urine albumin to creatinine ratio, kidney failure risk equation measurements for each individual | 5 years |
| estimated Glomerular Filtration Rate slope | Tracking changes in estimated Glomerular Filtration Rate over time indicates progression of chronic kidney disease for each individual | 5 years |
| Number of individuals with 40 % decline in estimated Glomerular Filtration Rate | Number of individuals with 40 % decline in estimated Glomerular Filtration Rate | 5 years |
| Number of individuals with kidney failure | Number of individuals with kidney failure | 5 years |
| Number of individuals on dialysis | Number of individuals on dialysis | 5 years |
| Number of individuals to receive kidney transplant | Number of individuals to receive kidney transplant | 5 years |
| Number of individuals who have died | Number of individuals who have died | 5 years |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |